Go to the list of all blogs
Serhii Bondarenko's Avatar
published in Blogs
Aug 10, 2026
AAAU vs GLD: Cost Efficiency Meets Liquidity in Physical Gold ETFs

AAAU vs GLD: Cost Efficiency Meets Liquidity in Physical Gold ETFs

Key Takeaways

  • Both ETFs provide direct physical gold exposure by holding allocated gold bullion, tracking the LBMA Gold Price PM with minimal tracking error over time.
  • Goldman Sachs Physical Gold ETF (AAAU) offers a significantly lower expense ratio of 0.18% compared to SPDR Gold Shares (GLD) at 0.40%, providing a structural cost advantage for long-term holders.
  • Each fund maintains a single holding of physical gold bars stored in secure vaults, resulting in identical exposure profiles without equity or sector diversification.
  • SPDR Gold Shares (GLD) delivers superior liquidity and tighter bid-ask spreads due to its substantially larger scale and longer trading history since 2004.
  • Both funds operate as passively managed grantor trusts with no active management, leverage, or rebalancing requirements, focusing purely on gold price performance net of expenses.
  • Relative positioning favors cost efficiency for Goldman Sachs Physical Gold ETF (AAAU) while liquidity and market depth support SPDR Gold Shares (GLD) for larger or frequent trades.

Why These Gold ETFs Stand Out

Goldman Sachs Physical Gold ETF (AAAU) and SPDR Gold Shares (GLD) stand as two prominent choices for investors seeking straightforward exposure to physical gold prices. These funds do not aim to replace equity or bond strategies but instead offer direct commodity participation without the need to store bullion personally. In today’s setting of macroeconomic uncertainty, currency shifts, and evolving rate expectations, both help clarify trade-offs around costs, liquidity, and structural simplicity when adding gold as a portfolio diversifier.

Goldman Sachs Physical Gold ETF (AAAU) at a Glance

The Goldman Sachs Physical Gold ETF (AAAU) is a passively managed grantor trust that tracks the price of gold bullion after expenses. It holds physical gold bars in allocated accounts at qualified custodians. The fund’s single primary holding is physical gold, with no equity stakes or sector allocations. Its expense ratio is 0.18%. Launched in 2018, it emphasizes cost efficiency and tracks the LBMA Gold Price PM benchmark. Features include fractional gold ownership per share and no lending of the underlying metal, which supports clean exposure for those focused on long-term commodity trends. I also checked this using Tickeron’s AI Screener to see how it stacks up against other gold vehicles.

SPDR Gold Shares (GLD) at a Glance

SPDR Gold Shares (GLD) is likewise a passively managed grantor trust that follows the price of gold bullion minus expenses. It stores allocated physical gold bars in secure London vaults. Like its counterpart, the fund holds only physical gold without additional securities. The expense ratio is 0.40%. Established in 2004, it also references the LBMA Gold Price PM. Its scale supports large custody setups and creation-redemption mechanisms that have helped build a strong market presence. From what I see, this structure has contributed to its deep trading liquidity over the years.

The Gold ETF Sector Context

The physical gold ETF space sits within the broader commodities and precious metals arena, shaped by factors such as inflation expectations, geopolitical events, central bank buying, and real interest rate movements. Gold has long served as a hedge against currency weakness and equity volatility. Flows into these products often rise during uncertain economic periods or when policy turns more accommodative. Regulatory focus remains on custody standards and holdings transparency, while risks involve storage costs, vault counterparty elements, and potential tax treatment changes for collectibles. These influences affect both ETFs in similar ways, underscoring why expense ratios and liquidity matter in allocation decisions.

Performance and Positioning Side by Side

Over recent cycles, both ETFs have tracked gold price movements closely, with differences stemming mainly from expense ratios rather than strategy divergence. When gold prices rise amid rate shifts or geopolitical developments, the lower-cost profile of Goldman Sachs Physical Gold ETF (AAAU) tends to retain more of the spot return. SPDR Gold Shares (GLD) benefits from higher trading volume, which usually translates to narrower spreads and smoother execution for larger positions. Volatility remains aligned given the identical physical backing. One thing that stands out is how Goldman Sachs Physical Gold ETF (AAAU) holds an efficiency edge for extended holding periods, while SPDR Gold Shares (GLD) offers advantages in high-liquidity situations.

Tickeron AI Assessment

Based on structural factors, Tickeron’s AI currently assigns a modest probabilistic preference to Goldman Sachs Physical Gold ETF (AAAU) owing to its lower expense ratio, which supports better net returns in gold price trends alongside an efficient single-asset setup and competitive tracking. SPDR Gold Shares (GLD) remains a solid option when liquidity depth takes priority. The evaluation balances cost efficiency and neutrality against scale advantages in a measured way.

Enhancing Research with Tickeron’s AI Screener

I often turn to Tickeron’s AI Screener when comparing ETFs like these to quickly filter on expense ratios, tracking metrics, and industry peers. It helps surface relevant ideas without manual effort and supports more informed decisions on cost versus liquidity trade-offs.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: GLD, AAAU

Contributor

Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.


GLD's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for GLD turned positive on July 02, 2026. Looking at past instances where GLD's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 05, 2026. You may want to consider a long position or call options on GLD as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

GLD moved above its 50-day moving average on August 05, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GLD advanced for three days, in of 345 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GLD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

GLD broke above its upper Bollinger Band on August 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for GLD entered a downward trend on July 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Industry description

The investment seeks to reflect the performance of the price of gold bullion, less the expenses of the Trust’s operations. The Trust holds gold bars and from time to time, issues Baskets in exchange for deposits of gold and distributes gold in connection with redemptions of Baskets. The investment objective of the Trust is for the Shares to reflect the performance of the price of gold bullion, less the Trust’s expenses. The Sponsor believes that, for many investors, the Shares represent a cost-effective investment in gold.
View a ticker or compare two or three
GLD
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Category CommoditiesBroadBasket

Profile
Details
Category
Commodities Focused
Address
444 Madison Ave, 3rd Flc/o World Gold Trust Services, LLCNew York
Phone
N/A
Web
http://www.spdrs.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.